FDA Approves Pembrolizumab for Tumors with Specific Genetic Features

FDA approved pembrolizumab for patients with solid tumors that have specific genetic features, called mismatch repair deficiency and high microsatellite instability. This is the first approval based on a genetic feature, rather than cancer type.

Cancer Currents: An NCI Cancer Research Blog